{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:16:46Z","timestamp":1760908606202,"version":"3.41.2"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/igc.0b013e3182098002","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T23:57:47Z","timestamp":1295999867000},"page":"263-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Potential Survival Benefit of Secondary Cytoreductive Surgery for Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancers"],"prefix":"10.1016","volume":"21","author":[{"given":"Tomoko","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morikazu","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Sasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e3182098002_bb0005","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer"},{"key":"10.1097\/IGC.0b013e3182098002_bb0010","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/1097-0142(19921015)70:8<2129::AID-CNCR2820700820>3.0.CO;2-U","article-title":"Radical surgical procedure improves survival time in patients with recurrent ovarian cancer","volume":"70","author":"Janicke","year":"1992","journal-title":"Cancer"},{"key":"10.1097\/IGC.0b013e3182098002_bb0015","first-page":"434","article-title":"Secondary cytoreduction for ovarian cancer following cisplatin therapy","volume":"11","author":"Segna","year":"1993","journal-title":"Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0020","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1006\/gyno.2000.5992","article-title":"Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer","volume":"79","author":"Gadducci","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0025","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1006\/gyno.2001.6404","article-title":"Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma","volume":"83","author":"Scarabelli","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0030","first-page":"1008","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"99","author":"Tay","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0035","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.20106","article-title":"Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?","volume":"100","author":"Zang","year":"2004","journal-title":"Cancer"},{"key":"10.1097\/IGC.0b013e3182098002_bb0040","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/sj.bjc.6602466","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection","volume":"92","author":"Onda","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1097\/IGC.0b013e3182098002_bb0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajog.2005.06.048","article-title":"The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience","volume":"194","author":"Ayhan","year":"2006","journal-title":"Am J Ostet Gynecol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0050","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1097\/IGC.0b013e3182098002_bb0055","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1245\/s10434-006-9273-8","article-title":"Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer","volume":"14","author":"Benedetti Panici","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0060","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","article-title":"Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome","volume":"109","author":"Salani","year":"2007","journal-title":"Cancer"},{"key":"10.1097\/IGC.0b013e3182098002_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3802\/jgo.2009.20.2.101","article-title":"Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer","volume":"20","author":"Bae","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0070","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","article-title":"Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis","volume":"16","author":"Harter","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0075","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jso.21470","article-title":"Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer","volume":"101","author":"Park","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jso.21491","article-title":"Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1\u20131 cm after secondary cytoreduction","volume":"101","author":"Tian","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0085","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jso.21686","article-title":"Survival after secondary cytoreduction for recurrent ovarian cancer: which are the prognostic factors?","volume":"102","author":"Biliatis","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0090","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jso.21652","article-title":"Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients","volume":"102","author":"Sehouli","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0095","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejso.2010.04.012","article-title":"Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer","volume":"36","author":"Woelber","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0100","unstructured":"Treatment Guidelines for Ovarian Cancer 2007 Edition. Japan Society of Gynecologic Oncology."},{"key":"10.1097\/IGC.0b013e3182098002_bb0105","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/IGC.0b013e3182098002_bb0110","first-page":"2817","article-title":"Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction","volume":"29","author":"Mahner","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1097\/IGC.0b013e3182098002_bb0115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2010.01.014","article-title":"Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?","volume":"117","author":"Tanner","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0120","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomized trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"10.1097\/IGC.0b013e3182098002_bb0125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2010.44","article-title":"Ovarian cancer: the duplicity of CA125 measurement","volume":"7","author":"Karam","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CCO.0b013e32833ae8b6","article-title":"How to follow-up patients with epithelial ovarian cancer","volume":"22","author":"Miller","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"10.1097\/IGC.0b013e3182098002_bb0135","first-page":"CD007822","article-title":"Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer","volume":"6","author":"Galaal","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1097\/IGC.0b013e3182098002_bb0140","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/IGC.0b013e3181e82a7f","article-title":"Clinical utility of positron emission tomography\/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels","volume":"20","author":"Bhosale","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1097\/IGC.0b013e3182098002_bb0145","doi-asserted-by":"crossref","unstructured":"Pan HS, Lee SL, Huang LW, et al. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer. Arch Gynecol Obstet. 2010. [Epub ahead of print].","DOI":"10.1007\/s00404-010-1404-6"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24037927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24037927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e3182098002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:23:49Z","timestamp":1753223029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24037927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1048891X24037927"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e3182098002","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Survival Benefit of Secondary Cytoreductive Surgery for Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancers","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e3182098002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}